Dr Sahar Kandil
Teams and roles for Sahar Kandil
Publication
2021
2020
2019
2018
2016
- Bassetto, M. et al. 2016. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry 118 , pp.230-243. (10.1016/j.ejmech.2016.04.052)
- Ferla, S. et al. 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15), pp.3636-3640. (10.1016/j.bmcl.2016.06.001)
- Kandil, S. et al. 2016. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Biorganic and Medicinal Chemistry Letters 26 (23), pp.5618-5623. (10.1016/j.bmcl.2016.10.077)
- Kandil, S. , Westwell, A. D. and McGuigan, C. 2016. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Biorganic and Medicinal Chemistry Letters 26 (8), pp.2000-2004. (10.1016/j.bmcl.2016.02.088)
- Kandil, S. et al. 2016. Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. European Journal of Medicinal Chemistry 110 , pp.311-325. (10.1016/j.ejmech.2015.12.037)
2014
2013
2009
2008
Articles
- Bassetto, M. et al. 2016. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. European Journal of Medicinal Chemistry 118 , pp.230-243. (10.1016/j.ejmech.2016.04.052)
- Dart, D. A. et al. 2018. Novel trifluoromethylated enobosarm analogues with potent antiandrogenic activity in vitro and tissue selectivity in vivo. Molecular Cancer Therapeutics 17 (9), pp.1846-1858. (10.1158/1535-7163.MCT-18-0037)
- Ferla, S. et al. 2016. Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. Bioorganic and Medicinal Chemistry Letters 26 (15), pp.3636-3640. (10.1016/j.bmcl.2016.06.001)
- Kandil, S. et al. 2016. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. Biorganic and Medicinal Chemistry Letters 26 (23), pp.5618-5623. (10.1016/j.bmcl.2016.10.077)
- Kandil, S. et al. 2009. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorganic & Medicinal Chemistry Letters 19 (11), pp.2935-2937. (10.1016/j.bmcl.2009.04.074)
- Kandil, S. et al. 2019. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. European Journal of Medicinal Chemistry 167 , pp.49-60. (10.1016/j.ejmech.2019.01.054)
- Kandil, S. et al. 2019. Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. Bioorganic and Medicinal Chemistry Letters 29 (24) 126721. (10.1016/j.bmcl.2019.126721)
- Kandil, S. et al. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91 (1), pp.314-321. (10.1111/cbdd.13083)
- Kandil, S. , Westwell, A. D. and McGuigan, C. 2016. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Biorganic and Medicinal Chemistry Letters 26 (8), pp.2000-2004. (10.1016/j.bmcl.2016.02.088)
- Kandil, S. et al. 2016. Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. European Journal of Medicinal Chemistry 110 , pp.311-325. (10.1016/j.ejmech.2015.12.037)
- Kandil, S. B. et al. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25 (15) 3488. (10.3390/molecules25153488)
- Kandil, S. B. et al. 2021. Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer. Bioorganic and Medicinal Chemistry Letters 36 127817. (10.1016/j.bmcl.2021.127817)
- Kandil, S. B. , McGuigan, C. and Westwell, A. D. 2021. Synthesis and biological evaluation of bicalutamide analogues for the potential treatment of prostate cancer. Molecules 26 (1) 56. (10.3390/molecules26010056)
- McGuigan, C. et al. 2013. Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. European Journal of Medicinal Chemistry 70 , pp.326-340. (10.1016/j.ejmech.2013.09.047)
- McGuigan, C. et al. 2014. ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. Bioorganic and Medicinal Chemistry 22 (9), pp.2816-2824. (10.1016/j.bmc.2014.02.056)
- Pertusati, F. et al. 2019. A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. European Journal of Medicinal Chemistry 180 , pp.1-14. (10.1016/j.ejmech.2019.07.001)
- Romagnoli, R. et al., 2008. Synthesis and biological evaluation of 2-amino-3-(3 ',4 ',5 '-trimethoxybenzoyl)-6-substituted-4,5,6,7-tetrahydrothieno 2,3-c pyridi ne derivatives as antimitotic agents and inhibitors of tubulin polymerization. Bioorganic & Medicinal Chemistry Letters 18 (18), pp.5041-5045. (10.1016/j.bmcl.2008.08.006)
Thesis